Search research articles
Contact Us
Filters
Showing results (101-110 of 122) with videos related to
Page
of 13
Sort By:
Blood Advances
|
August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study
Nirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Blood Neoplasia
|
June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy
Joshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Blood Advances
|
May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
Joseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
Internal Medicine Journal
|
May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic
Pietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood Advances
|
October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Joshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.
Blood Advances
|
January 7, 2026
Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma
Gloria Iacoboni, Emil Kyvsgaard, Víctor Navarro, et al.
Blood Advances
|
January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Krish Patel, Julie M Vose, Sunita D Nasta, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Blood
|
April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy
Prokop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 122) with videos related to
Sort By:
Page
of 13
Blood Advances
|
August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study
Nirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Blood Neoplasia
|
June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy
Joshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Blood Advances
|
May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
Joseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
Internal Medicine Journal
|
May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic
Pietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood Advances
|
October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Joshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.
Blood Advances
|
January 7, 2026
Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma
Gloria Iacoboni, Emil Kyvsgaard, Víctor Navarro, et al.
Blood Advances
|
January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Krish Patel, Julie M Vose, Sunita D Nasta, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Blood
|
April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy
Prokop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Page
of 13